Author

Alan Meehan

PREDICTORS OF CLINICAL RESPONSE AND INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IMPROVEMENT WITH GOLIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS IN THE PURSUIT-MAINTENANCE STUDY
PREDICTORS OF CLINICAL RESPONSE AND INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IMPROVEMENT WITH GOLIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS IN THE PURSUIT-MAINTENANCE STUDY

Alan Meehan  et al.

QUALITY OF LIFE OUTCOMES FROM PURSUIT-M TRIAL FURTHER SUPPORT EARLY DOSE OPTIMIZATION OF GOLIMUMAB IN MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS
QUALITY OF LIFE OUTCOMES FROM PURSUIT-M TRIAL FURTHER SUPPORT EARLY DOSE OPTIMIZATION OF GOLIMUMAB IN MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS

Alan Meehan  et al.

PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Alan Meehan  et al.

Item 1 - 3 / 3
1